| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 4.96M | 36.93M | 91.25M | 182.24M | 260.89M | 305.51M | 329.23M | 399.36M | 528.29M |
| Revenue Growth % | -1% | - | 6.45% | 1.47% | 1% | 0.43% | 0.17% | 0.08% | 0.21% | 0.32% |
| Cost of Goods Sold | 1.83M | 833K | 6.24M | 14.4M | 21.96M | 31.04M | 34.47M | 38.6M | 37.33M | 52.94M |
| COGS % of Revenue | - | 0.17% | 0.17% | 0.16% | 0.12% | 0.12% | 0.11% | 0.12% | 0.09% | 0.1% |
| Gross Profit | -1.83M | 4.13M | 30.69M | 76.84M | 160.27M | 229.84M | 271.05M | 290.63M | 362.03M | 475.35M |
| Gross Margin % | - | 0.83% | 0.83% | 0.84% | 0.88% | 0.88% | 0.89% | 0.88% | 0.91% | 0.9% |
| Gross Profit Growth % | -2.5% | 3.25% | 6.44% | 1.5% | 1.09% | 0.43% | 0.18% | 0.07% | 0.25% | 0.31% |
| Operating Expenses | 126.05M | 179.19M | 241.57M | 402.32M | 464.31M | 476.84M | 477.48M | 502.75M | 439.24M | 450.48M |
| OpEx % of Revenue | - | 36.14% | 6.54% | 4.41% | 2.55% | 1.83% | 1.56% | 1.53% | 1.1% | 0.85% |
| Selling, General & Admin | 47.27M | 71.15M | 88.67M | 127.2M | 169.86M | 156.41M | 192.71M | 213.04M | 275.27M | 323.38M |
| SG&A % of Revenue | - | 14.35% | 2.4% | 1.39% | 0.93% | 0.6% | 0.63% | 0.65% | 0.69% | 0.61% |
| Research & Development | 76.94M | 104.79M | 149.31M | 270.9M | 286.38M | 308.44M | 272.05M | 276.68M | 152.38M | 109.36M |
| R&D % of Revenue | - | 21.14% | 4.04% | 2.97% | 1.57% | 1.18% | 0.89% | 0.84% | 0.38% | 0.21% |
| Other Operating Expenses | -80K | -4.79M | 6.01M | -5.63M | 8.07M | 11.99M | 12.72M | 13.04M | 11.59M | 17.73M |
| Operating Income | -130.44M | -181.89M | -441.99M | -328.78M | -304.04M | -247M | -206.43M | -212.12M | -77.21M | 24.88M |
| Operating Margin % | - | -36.69% | -11.97% | -3.6% | -1.67% | -0.95% | -0.68% | -0.64% | -0.19% | 0.05% |
| Operating Income Growth % | -0.9% | -0.39% | -1.43% | 0.26% | 0.08% | 0.19% | 0.16% | -0.03% | 0.64% | 1.32% |
| EBITDA | -128.6M | -178.65M | -438.39M | -324.56M | -299.26M | -238.15M | -200.22M | -206.78M | -69.34M | 33.42M |
| EBITDA Margin % | - | -36.03% | -11.87% | -3.56% | -1.64% | -0.91% | -0.66% | -0.63% | -0.17% | 0.06% |
| EBITDA Growth % | -0.92% | -0.39% | -1.45% | 0.26% | 0.08% | 0.2% | 0.16% | -0.03% | 0.66% | 1.48% |
| D&A (Non-Cash Add-back) | 1.83M | 3.24M | 3.59M | 4.22M | 4.78M | 8.85M | 6.21M | 5.34M | 7.87M | 8.55M |
| EBIT | -130.54M | -198.38M | -431.88M | -326.69M | -337.04M | -251.83M | -209.08M | -204.92M | -99.95M | 20.84M |
| Net Interest Income | -649K | -3.8M | -13.14M | -11.94M | -8.62M | -19.2M | -31.96M | -34.09M | -43.07M | -44.19M |
| Interest Income | 929K | 1.6M | 4.1M | 10.46M | 10.25M | 3.23M | 509K | 3.02M | 7.08M | 5.41M |
| Interest Expense | 1.58M | 5.4M | 17.24M | 22.4M | 18.87M | 22.43M | 32.47M | 37.12M | 50.15M | 49.6M |
| Other Income/Expense | -6.07M | -21.89M | -7.14M | -23.61M | -51.87M | -27.26M | -35.12M | -29.92M | -72.89M | -53.63M |
| Pretax Income | -132.12M | -203.78M | -449.12M | -349.09M | -355.91M | -274.25M | -241.55M | -242.04M | -150.1M | -28.76M |
| Pretax Margin % | - | -41.1% | -12.16% | -3.83% | -1.95% | -1.05% | -0.79% | -0.74% | -0.38% | -0.05% |
| Income Tax | 1.5M | -3.74M | -165.12M | -94K | 478K | 2.6M | 8.91M | -5.47M | 1.48M | 27.35M |
| Effective Tax Rate % | 1% | 0.98% | 0.63% | 1% | 1% | 1.01% | 1.04% | 0.98% | 1.01% | 1.95% |
| Net Income | -132.12M | -200.04M | -284M | -349M | -356.39M | -276.85M | -250.46M | -236.57M | -151.58M | -56.11M |
| Net Margin % | - | -40.35% | -7.69% | -3.82% | -1.96% | -1.06% | -0.82% | -0.72% | -0.38% | -0.11% |
| Net Income Growth % | -0.92% | -0.51% | -0.42% | -0.23% | -0.02% | 0.22% | 0.1% | 0.06% | 0.36% | 0.63% |
| Net Income (Continuing) | -132.12M | -200.04M | -284M | -349M | -356.39M | -276.85M | -250.46M | -236.57M | -151.58M | -56.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.20 | -1.49 | -1.85 | -1.88 | -1.48 | -1.07 | -0.92 | -0.82 | -0.51 | -0.18 |
| EPS Growth % | -0.29% | -0.24% | -0.24% | -0.02% | 0.21% | 0.28% | 0.14% | 0.11% | 0.38% | 0.65% |
| EPS (Basic) | -1.20 | -1.49 | -1.85 | -1.88 | -1.48 | -1.07 | -0.92 | -0.82 | -0.51 | -0.18 |
| Diluted Shares Outstanding | 109.92M | 134.4M | 153.36M | 185.79M | 240.42M | 258.87M | 271.42M | 289.06M | 295.16M | 304.38M |
| Basic Shares Outstanding | 109.92M | 134.4M | 153.36M | 185.79M | 240.42M | 258.87M | 271.42M | 289.06M | 295.16M | 304.38M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 216.6M | 340.06M | 391.96M | 551.1M | 520.07M | 579.47M | 596.83M | 423.82M | 483.06M | 504.74M |
| Cash & Short-Term Investments | 214.03M | 330.35M | 358.56M | 504.15M | 452.74M | 483.27M | 482.5M | 293.6M | 286.2M | 249.95M |
| Cash Only | 69.48M | 187.03M | 49.06M | 79.75M | 142.84M | 163.24M | 245.2M | 148.81M | 246.99M | 213.75M |
| Short-Term Investments | 144.55M | 143.32M | 309.5M | 424.4M | 309.9M | 320.03M | 237.3M | 144.78M | 39.21M | 36.19M |
| Accounts Receivable | 0 | 1.3M | 9.46M | 21.96M | 33.28M | 46.92M | 52.67M | 66.2M | 87.63M | 101.1M |
| Days Sales Outstanding | - | 96 | 93.54 | 87.85 | 66.66 | 65.65 | 62.93 | 73.39 | 80.09 | 69.85 |
| Inventory | 0 | 3.42M | 4.62M | 8.39M | 14.04M | 19.56M | 26.82M | 23.82M | 59.7M | 118.78M |
| Days Inventory Outstanding | - | 1.5K | 270.59 | 212.6 | 233.35 | 229.93 | 284.01 | 225.21 | 583.75 | 818.91 |
| Other Current Assets | 2.57M | 4.99M | 19.32M | 16.59M | 0 | 0 | 0 | 40.21M | 49.53M | 34.91M |
| Total Non-Current Assets | 691.78M | 696.78M | 235.06M | 238.85M | 330.13M | 307.05M | 308.31M | 300.35M | 294.82M | 280.3M |
| Property, Plant & Equipment | 6.18M | 9.82M | 9.06M | 11.38M | 81.02M | 67.16M | 63.08M | 60.31M | 57.98M | 51.66M |
| Fixed Asset Turnover | - | 0.51x | 4.08x | 8.02x | 2.25x | 3.88x | 4.84x | 5.46x | 6.89x | 10.23x |
| Goodwill | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M |
| Intangible Assets | 486.7M | 486.7M | 23M | 23M | 23M | 23M | 23M | 23M | 20.49M | 17.2M |
| Long-Term Investments | 0 | -173.77M | -6.46M | -6.46M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.11M | 2.47M | 5.2M | 6.68M | 28.32M | 19.09M | 24.43M | 19.24M | 18.55M | 13.64M |
| Total Assets | 908.38M | 1.04B | 627.02M | 789.95M | 850.21M | 886.52M | 905.14M | 724.17M | 777.88M | 785.03M |
| Asset Turnover | - | 0.00x | 0.06x | 0.12x | 0.21x | 0.29x | 0.34x | 0.45x | 0.51x | 0.67x |
| Asset Growth % | 3.33% | 0.14% | -0.4% | 0.26% | 0.08% | 0.04% | 0.02% | -0.2% | 0.07% | 0.01% |
| Total Current Liabilities | 73.62M | 110.96M | 70.04M | 86.13M | 128.81M | 129.68M | 145.97M | 139.02M | 167.69M | 148.7M |
| Accounts Payable | 16.48M | 12.9M | 7.87M | 6.61M | 21.72M | 17.06M | 21.51M | 15.41M | 15.12M | 12.95M |
| Days Payables Outstanding | 3.28K | 5.65K | 460.46 | 167.4 | 360.99 | 200.62 | 227.83 | 145.75 | 147.85 | 89.26 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1000K | 1000K | 1000K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 50.94M | 23.8M | 30.82M | 32.06M | 31.18M | 27.12M | 28.46M | 33.17M | 48.68M | 41.23M |
| Current Ratio | 2.94x | 3.06x | 5.60x | 6.40x | 4.04x | 4.47x | 4.09x | 3.05x | 2.88x | 3.39x |
| Quick Ratio | 2.94x | 3.03x | 5.53x | 6.30x | 3.93x | 4.32x | 3.90x | 2.88x | 2.52x | 2.60x |
| Cash Conversion Cycle | - | -4.06K | -96.34 | 133.06 | -60.99 | 94.96 | 119.11 | 152.85 | 515.99 | 799.5 |
| Total Non-Current Liabilities | 486.93M | 565.74M | 204.13M | 360.91M | 244.97M | 470.46M | 451.8M | 462.1M | 450.02M | 442.29M |
| Long-Term Debt | 41.6M | 154.46M | 164.17M | 321.74M | 149.5M | 389.25M | 389.36M | 391.99M | 387.86M | 390.11M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 53.53M | 45.6M | 43.36M | 51.58M | 48.88M | 45.08M |
| Deferred Tax Liabilities | 176.22M | 173.77M | 6.46M | 6.46M | 5.05M | 4.9M | 4.93M | 4.94M | 0 | 0 |
| Other Non-Current Liabilities | 269.11M | 237.5M | 33.5M | 32.71M | 36.88M | 30.71M | 14.15M | 13.6M | 13.28M | 7.1M |
| Total Liabilities | 560.55M | 676.69M | 274.17M | 447.04M | 373.78M | 600.14M | 597.77M | 601.12M | 617.71M | 590.99M |
| Total Debt | 41.6M | 154.46M | 164.47M | 321.74M | 210.22M | 441.73M | 440.13M | 452.12M | 445.06M | 443.64M |
| Net Debt | -27.88M | -32.56M | 115.41M | 241.99M | 67.39M | 278.49M | 194.93M | 303.31M | 198.06M | 229.89M |
| Debt / Equity | 0.12x | 0.43x | 0.47x | 0.94x | 0.44x | 1.54x | 1.43x | 3.67x | 2.78x | 2.29x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | 13.27x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 6.88x |
| Interest Coverage | -82.66x | -33.70x | -25.64x | -14.68x | -16.11x | -11.01x | -6.36x | -5.71x | -1.54x | 0.50x |
| Total Equity | 347.83M | 360.15M | 352.85M | 342.91M | 476.43M | 286.38M | 307.37M | 123.05M | 160.17M | 194.04M |
| Equity Growth % | 1.85% | 0.04% | -0.02% | -0.03% | 0.39% | -0.4% | 0.07% | -0.6% | 0.3% | 0.21% |
| Book Value per Share | 3.16 | 2.68 | 2.30 | 1.85 | 1.98 | 1.11 | 1.13 | 0.43 | 0.54 | 0.64 |
| Total Shareholders' Equity | 347.83M | 360.15M | 352.85M | 342.91M | 476.43M | 286.38M | 307.37M | 123.05M | 160.17M | 194.04M |
| Common Stock | 1.31M | 1.48M | 1.72M | 1.94M | 2.6M | 2.65M | 2.81M | 2.81M | 2.92M | 2.94M |
| Retained Earnings | -579.57M | -779.61M | -1.06B | -1.41B | -1.77B | -2.05B | -2.3B | -2.53B | -2.68B | -2.74B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -115K | 2.05M | -2.1M | 68K | 2.83M | 8.23M | 4.98M | -12.11M | 5.24M | 5.09M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -100.14M | -150.53M | -215.49M | -299.95M | -250.42M | -233.29M | -202.49M | -166.57M | -69.09M | -33.89M |
| Operating CF Margin % | - | -30.36% | -5.83% | -3.29% | -1.37% | -0.89% | -0.66% | -0.51% | -0.17% | -0.06% |
| Operating CF Growth % | -0.94% | -0.5% | -0.43% | -0.39% | 0.17% | 0.07% | 0.13% | 0.18% | 0.59% | 0.51% |
| Net Income | -132.12M | -200.04M | -284M | -349M | -356.39M | -276.85M | -250.46M | -236.57M | -151.58M | -56.11M |
| Depreciation & Amortization | 1.83M | 3.24M | 3.59M | 4.22M | 4.78M | 8.85M | 6.21M | 5.34M | 7.87M | 8.55M |
| Stock-Based Compensation | 9.97M | 17.5M | 23.1M | 29.26M | 44.43M | 49.15M | 57.84M | 76.51M | 86.08M | 84.91M |
| Deferred Taxes | 952K | -3.74M | -167.31M | 6.01M | -1.42M | -155K | 34K | 9K | -4.94M | 0 |
| Other Non-Cash Items | 4.88M | 31.37M | 234.91M | 14.28M | 46.57M | 17.78M | 2.47M | 28.01M | 41.47M | 27.71M |
| Working Capital Changes | 14.34M | 1.14M | -25.79M | -4.73M | 11.61M | -32.06M | -18.59M | -39.88M | -47.99M | -98.94M |
| Change in Receivables | 0 | -1.42M | -7.72M | -13.29M | -11.11M | -11.22M | -8.19M | -17.33M | -20.11M | -19.48M |
| Change in Inventory | 0 | -3.65M | -897K | -4.21M | -5.11M | -4.64M | -7.79M | -5.34M | -44.61M | -73.65M |
| Change in Payables | 15.47M | 7.13M | 12.56M | 17.11M | 46.74M | -10.61M | 7.43M | -6.38M | 49.2M | -16.52M |
| Cash from Investing | -145.34M | -4.51M | -171.24M | -121.2M | 95.15M | -13.58M | 78.76M | 92.32M | 98.06M | -560K |
| Capital Expenditures | -4.82M | -5.95M | -4.53M | -6.31M | -20.01M | -3.23M | -3.88M | -3.77M | -7.44M | -3.55M |
| CapEx % of Revenue | - | 1.2% | 0.12% | 0.07% | 0.11% | 0.01% | 0.01% | 0.01% | 0.02% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 534K | 1.44M | -166.72M | -6.31M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 290.89M | 272.71M | 247.43M | 450.77M | 217.5M | 262.86M | 212.07M | -7.46M | 61.68M | 5.12M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 13.14M | -16.7M | 4.71M | 9.93M | 28.93M | 32.25M | 12.8M | 0 | -20.57M | -22.02M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -104.96M | -156.49M | -220.01M | -306.26M | -270.43M | -236.52M | -206.38M | -170.34M | -76.53M | -37.44M |
| FCF Margin % | - | -31.56% | -5.96% | -3.36% | -1.48% | -0.91% | -0.68% | -0.52% | -0.19% | -0.07% |
| FCF Growth % | -1.02% | -0.49% | -0.41% | -0.39% | 0.12% | 0.13% | 0.13% | 0.17% | 0.55% | 0.51% |
| FCF per Share | -0.95 | -1.16 | -1.43 | -1.65 | -1.12 | -0.91 | -0.76 | -0.59 | -0.26 | -0.12 |
| FCF Conversion (FCF/Net Income) | 0.76x | 0.75x | 0.76x | 0.86x | 0.70x | 0.84x | 0.81x | 0.70x | 0.46x | 0.60x |
| Interest Paid | 0 | 0 | 0 | 7.5M | 16.97M | 24.68M | 30.47M | 34.36M | 36.09M | 58.96M |
| Taxes Paid | 0 | 0 | 0 | 1.06M | 691K | 10.37M | 20.03M | 1.07M | 8.53M | 8.21M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -56.22% | -56.51% | -79.66% | -100.32% | -86.99% | -72.59% | -84.37% | -109.93% | -107.04% | -31.68% |
| Return on Invested Capital (ROIC) | -45.25% | -42.13% | -83.3% | -46.83% | -40.4% | -33.42% | -29.02% | -34.26% | -14.76% | 4.77% |
| Gross Margin | - | 83.2% | 83.11% | 84.21% | 87.95% | 88.1% | 88.72% | 88.28% | 90.65% | 89.98% |
| Net Margin | - | -4034.73% | -769.03% | -382.48% | -195.56% | -106.12% | -81.98% | -71.85% | -37.96% | -10.62% |
| Debt / Equity | 0.12x | 0.43x | 0.47x | 0.94x | 0.44x | 1.54x | 1.43x | 3.67x | 2.78x | 2.29x |
| Interest Coverage | -82.66x | -33.70x | -25.64x | -14.68x | -16.11x | -11.01x | -6.36x | -5.71x | -1.54x | 0.50x |
| FCF Conversion | 0.76x | 0.75x | 0.76x | 0.86x | 0.70x | 0.84x | 0.81x | 0.70x | 0.46x | 0.60x |
| Revenue Growth | -100% | - | 644.86% | 147.08% | 99.72% | 43.16% | 17.11% | 7.76% | 21.3% | 32.29% |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Non-US | 129.76M | 180.84M | 210.13M | 213.29M | 252.42M | 282.03M |
| Non-US Growth | - | 39.37% | 16.19% | 1.50% | 18.35% | 11.73% |
| UNITED STATES | 52.48M | 80.05M | 95.39M | 115.95M | 146.94M | 176.02M |
| UNITED STATES Growth | - | 52.53% | 19.17% | 21.55% | 26.73% | 19.80% |
Amicus Therapeutics, Inc. (FOLD) reported $598.7M in revenue for fiscal year 2024. This represents a 2693% increase from $21.4M in 2011.
Amicus Therapeutics, Inc. (FOLD) grew revenue by 32.3% over the past year. This is strong growth.
Amicus Therapeutics, Inc. (FOLD) reported a net loss of $14.1M for fiscal year 2024.
Amicus Therapeutics, Inc. (FOLD) has a return on equity (ROE) of -31.7%. Negative ROE indicates the company is unprofitable.
Amicus Therapeutics, Inc. (FOLD) generated $9.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.